Non-dilutive funding leverage G2G has secured substantial non-dilutive funding totaling 550 million since 2007, indicating strong capabilities in funding advocacy and grant access that can be cross-sold to startups and bioscience clients seeking government grants and BAAs.

Healthcare and bioscience focus With a strong healthcare, bioscience, and women’s health advocacy practice, there is a clear opportunity to target biotech, medtech, and life sciences companies seeking regulatory navigation and federal funding opportunities.

Capitol Hill access G2G’s established relationships on Capitol Hill, with agencies and the White House, can be positioned as a differentiator for clients needing strategic policy influence, congressional engagement, and regulatory shaping.

Strategic partnerships Recent collaborations with iBIO Institute and Focused Ultrasound Foundation demonstrate a track record of co-sponsoring government funding outreach; this suggests potential for formal partner programs or co-branded grant opportunity campaigns.

Growth and scale signal Revenue is in the 1–10 million range with a lean team (11–50 employees), indicating velocity and agility ideal for mid-market startups and nonprofits seeking cost-effective, attentive government affairs support.